Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma

NCT00278525 | Completed Phase 2 Results

• 1 other identifier: DI Scl.Randomized2004
• Study Type: interventional
• Target: 19
• Locations: 1 country
• Sites: 1

Brief Summary

Scleroderma is a systemic disorder categorized as an immunologically mediated disease that causes collagen deposition of skin and visceral organs. The molecular pathogenesis of scleroderma has been elusive, although vasculopathy and immune mediated mechanisms are thought to be important. Once extensive cutaneous or visceral disease occurs, prognosis is significantly shorter than the general population. Although various treatments have been tried, none of them seems to have changed the natural history of scleroderma. Standard dose immunosuppressive treatment has been disappointing. Recently, cyclophosphamide at 1-2 mg/kg/day orally or 800-1400 mg intravenous (IV) monthly for 6-9 months has proven effective in treatment of scleroderma alveolitis (1). Recent phase I studies of immunoablation with autologous peripheral blood stem cell transplantation (PBSCT) showed some promising data, but the exact efficacy is undetermined (2,3). We now propose, as a phase II randomized study, autologous unmanipulated PBSCT versus pulse cyclophosphamide in patients with systemic scleroderma.

Conditions

SYSTEMIC SCLERODERMA

Outcome Measures

Primary Outcomes (2)

• Time to Treatment Failure

  -Data are reporting number of participants that were classified as treatment failures Time to Treatment Failure Definition-Treatment failure will not occur until a minimum of 12 months after enrollment at which time failure is defined as: 1. Failure of skin score (if \> 14 on enrollment) to improve or increase in skin score by a 25% above lowest post treatment value and must be documented on 2 occasion 6 months apart 2. Deterioration in diffusing capacity of the lung for carbon monoxide (DLCO), diffusing capacity divided by the alveolar volume (DLCO/VA) or forced vital capacity (FVC) by 10% below enrollment level or 10% below best post treatment value, due to systemic sclerosis, and documented on 2 occasion 6 months apart 3. Renal failure due to systemic sclerosis and defined as chronic dialysis for more than 12 months 4. Gastrointestinal failure due to systemic sclerosis and defined as initiation of total parenteral nutrition(TPN) for more than 12 months

  12 months

• Disease Improvement

  Data are reporting number of participants that were classified as disease improvement. Definition of disease improvement: Disease improvement defined by at least 25% improvement in skin score (Rodnan), or 10% improvement in pulmonary function tests \[diffusing capacity of the lung for carbon monoxide (DLCO), diffusing capacity divided by the alveolar volume (DLCO/VA), or forced vital capacity (FVC)\], or in cardiac tests \[pulmonary artery (PA) systolic pressure by right heart cath\] that persists \> 6 months or ability to wean off total parenteral nutrition (TPN)

  12 months

Study Arms (2)

stem cell trasplantation

EXPERIMENTAL

intervention as stem cell transplantation after conditioning regimen

Procedure: stem cell transplantation

standard of care

ACTIVE COMPARATOR

medication as standard of care will be given

Drug: standard of care

Interventions

standard of care DRUG

standard of care medication will be given

standard of care

stem cell transplantation PROCEDURE

The following is intervention: stem cell transplantation after conditioning regimen

Also known as: stem cell transplant, stem cell injection

stem cell trasplantation

Eligibility Criteria

• Age: Up to 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Age 60 year or \< 60 year old at the time of pretransplant evaluation.
• An established diagnosis of scleroderma.
• Diffuse cutaneous scleroderma with involvement proximal to the elbow or knee and a Rodnan score of \> 14
• AND
• Scleroderma with any one of the following:
• Diffusing capacity of the lung for carbon monoxide (DLCO) \< 80% of predicted or decrease in lung function \[DLCO, diffusing capacity divided by the alveolar volume (DLCO/VA) or forced vital capacity (FVC) \] of 10% or more over 12 months.
• Active alveolitis on bronchoalveolar lavage.
• Pulmonary fibrosis or alveolitis on computed tomography (CT) scan or chest x-ray (CXR) (ground glass appearance of alveolitis).
• Renal disease that is not explained by a bacterial infection or other renal disorders. (Subjects must have two or more of the following: proteinuria - greater than trace on dipstick, hematuria - urine blood on dipstick or sediment, hypertension that requires treatment with anti-hypertensive medications or untreated but with a diastolic blood pressure (BP) \> 95 mm/hg.)
• Abnormal electrocardiogram (EKG) (non-specific ST-T wave abnormalities, low QRS voltage, or ventricular hypertrophy), or pericardial effusion or pericardial enhancement on magnetic resonance imaging (MRI)
• Gastrointestinal tract involvement confirmed on radiological study. Radiologic findings of scleroderma are small bowel radiographs showing thickened folds with dilated loops, segmentation, and flocculation +/- diverticulae, or pseudodiverticulae. A hide-bound appearance due to valvulae packing i.e. dilated and crowded circular folds, may be present. Gastrointestinal (GI) involvement may also be confirmed by D-xylose malabsorption, patulous esophagus, or esophageal manometry.
• As published in NEJM, 2006, 345:25 2655-2709. Limited or diffuse SSL with lung involvement defined as active alveolitis on bronchoalveolar lavage (BAL) or ground-glass opacity on CT, a DLCO \< 80% predicted or decrease in lung function (DLCO/VA,DLCO, FVC) of 10% or more in last 12 months.

You may not qualify if:

• Poor performance status Eastern Cooperative Oncology Group (ECOG 2) at the time of entry.
• Significant end organ damage such as:
• Left Ventricular Ejection Fraction (LVEF) \< 40% or deterioration of LVEF during exercise test on Multiple Gated Acquisition (MUGA) or echocardiogram.
• Untreated life-threatening arrhythmia.
• Active ischemic heart disease or heart failure.
• End-stage lung disease characterized by total lung capacity (TLC) \<45% of predicted value.
• Pulmonary hypertension (systolic pulmonary arterial pressure \> 40 mmHg or mean pulmonary arterial pressure (PAP) \> 25 mmHG measurement by pulmonary arterial catheter).
• Serum creatinine \> 2.0 mg/dl.
• Liver cirrhosis, transaminases \> 3x of normal limits or bilirubin \> 2.0 unless due to Gilberts disease.
• Pericardial effusion\> 200ml unless successful pericardiocentesis
• Tricuspid annular peak systolic excursion (TAPSE) ≤ 1.9 cm
• MRI of heart showing D sign (intraventricular flattering)
• Human immunodeficiency virus (HIV) positive.
• Uncontrolled diabetes mellitus, or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive treatment.
• Prior history of malignancy except localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as (but not limited to) head and neck cancer, or stage I or II breast cancer will be considered on an individual basis.

Sponsors & Collaborators

• Northwestern University: lead

Study Sites (1)

Northwestern University, Feinberg School of Medicine

Chicago, Illinois, 60611, United States

Location

Related Publications (2)

• Bruera S, Sidanmat H, Molony DA, Mayes MD, Suarez-Almazor ME, Krause K, Lopez-Olivo MA. Stem cell transplantation for systemic sclerosis. Cochrane Database Syst Rev. 2022 Jul 29;7(7):CD011819. doi: 10.1002/14651858.CD011819.pub2.

  PMID: 35904231 DERIVED

• Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, Craig R, Hirano I, Marshall K, Ruderman E, Jovanovic B, Milanetti F, Jain S, Boyce K, Morgan A, Carr J, Barr W. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011 Aug 6;378(9790):498-506. doi: 10.1016/S0140-6736(11)60982-3. Epub 2011 Jul 21.

  PMID: 21777972 DERIVED

MeSH Terms

Conditions

Scleroderma, Systemic

Interventions

Standard of Care; Stem Cell Transplantation

Condition Hierarchy (Ancestors)

Connective Tissue Diseases; Skin and Connective Tissue Diseases; Skin Diseases

Intervention Hierarchy (Ancestors)

Quality Indicators, Health Care; Quality of Health Care; Health Services Administration; Health Care Quality, Access, and Evaluation; Cell Transplantation; Cell- and Tissue-Based Therapy; Biological Therapy; Therapeutics; Transplantation; Surgical Procedures, Operative

Results Point of Contact

• Title: Dr. Richard Burt
• Organization: Northwestern University

rburt@northwestern.edu

312-908-0059

Study Officials

• Richard Burt, MD

  Northwestern University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: January 15, 2006
• First Posted: January 18, 2006
• Study Start: September 1, 2005
• Primary Completion: September 1, 2011
• Study Completion: December 1, 2012
• Last Updated: April 30, 2014
• Results First Posted: April 30, 2014

Record last verified: 2014-03

Locations

US (1)